📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
502 analysed today
FollowTelegram
502
Today
149,903
All-time analysed
42,967
Positive
6,669
Negative
91,560
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
251 announcements match the current filters (relevance ≥ 5).
HAL CMD Dr. D K Sunil Retires Following Superannuation on April 30, 2026
Hindustan Aeronautics Limited (HAL) has announced that Dr. D K Sunil has ceased to be the Chairman & Managing Director (CMD) of the company effective April 30, 2026. This departure is due to his superannuation, concluding a tenure that officially began on September 9, 2024. As a key leadership role in a major defense PSU, the transition to a successor will be critical for maintaining the momentum of ongoing projects and order execution. Investors should look for the official announcement regarding the new leadership appointment.
Key Highlights
Dr. D K Sunil retired as Chairman & Managing Director effective April 30, 2026.
The cessation of office is due to superannuation after serving since September 2024.
Sunil had also held additional charge as CMD from September 1 to September 8, 2024.
The transition is a routine administrative process for the state-run defense major.
👀 What to Watch
Monitor the announcement of the new CMD to ensure leadership continuity. No immediate action is required as this is a planned retirement.
HAL CMD Dr. D K Sunil Steps Down Effective April 30, 2026, Due to Superannuation
Hindustan Aeronautics Limited (HAL) has announced that Dr. D K Sunil has ceased to be the Chairman & Managing Director effective April 30, 2026. This change is a result of his scheduled superannuation after serving in the top leadership role since September 2024. The transition is a routine administrative event for the Public Sector Undertaking and does not indicate any internal governance issues. Investors should now look for the government's announcement regarding a successor to ensure continuity in HAL's strategic defense projects.
Key Highlights
Dr. D K Sunil ceased as Chairman & Managing Director on April 30, 2026.
The departure is due to superannuation (retirement) and not a resignation.
He served as CMD from September 9, 2024, to April 30, 2026.
The filing was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
👀 What to Watch
This is a routine retirement; investors should remain focused on the company's order book and monitor for the appointment of a new CMD to ensure leadership stability.
Halder Venture Shareholders Approve Capital Increase and Preferential Warrant Issue
Halder Venture Limited has received overwhelming shareholder approval for two major resolutions via postal ballot. The first resolution involves increasing the company's Authorized Share Capital, which passed with 99.9998% support. The second resolution, passed with 99.9973% support, authorizes the issuance of fully convertible warrants on a preferential basis to non-promoter entities. This indicates strong shareholder backing for the company's upcoming capital infusion and expansion plans.
Key Highlights
Resolution to increase Authorized Share Capital passed with 9,537,125 votes (99.9998%) in favor.
Issuance of fully convertible warrants to non-promoters approved with 9,536,878 votes (99.9973%) in favor.
A total of 79 members participated in the remote e-voting process which concluded on April 29, 2026.
The approval allows the company to proceed with preferential allotment to non-promoter categories for fund raising.
👀 What to Watch
Investors should monitor the specific pricing and allotment details of the convertible warrants to understand the extent of equity dilution and the profile of the new investors entering the company.
Chalet Hotels Completes Tranche 1 Acquisition of Seasons Hotels Private Limited
Chalet Hotels Limited has announced the successful completion of Tranche 1 for the acquisition of Seasons Hotels Private Limited. As a result of this transaction, Seasons Hotels has officially become a subsidiary of Chalet Hotels. This move follows the company's previous strategic announcements made in December 2025 and April 2024 regarding its expansion plans. The acquisition is expected to bolster Chalet's presence in the hospitality market and contribute to its long-term growth strategy.
Key Highlights
Completion of Tranche 1 acquisition of Seasons Hotels Private Limited
Seasons Hotels Private Limited has officially become a subsidiary of the Company
Follows previous regulatory intimations dated December 11, 2025, and April 24, 2026
Transaction executed under Regulations 30 and 51 of SEBI Listing Regulations
👀 What to Watch
Investors should view this as a positive step in Chalet's inorganic growth strategy and monitor the subsequent tranches and integration of the new subsidiary. Watch for updates on how this acquisition impacts the company's total room inventory and consolidated EBITDA margins.
Halder Venture Issues 2nd Corrigendum for 7.93 Lakh Warrant Issue at ₹315
Halder Venture Limited has issued a second corrigendum to its postal ballot notice regarding the preferential issue of 7,93,650 convertible warrants. The issue price is fixed at ₹315 per warrant, which includes a premium of ₹305, based on an independent valuation of ₹314.79. This update follows observations from the National Stock Exchange (NSE) to ensure compliance with SEBI ICDR Regulations for infrequently traded shares. The proposed allotment will result in the allottee holding more than 5% of the post-issue fully diluted share capital.
Key Highlights
Preferential issue of 7,93,650 convertible warrants at a price of ₹315 per warrant.
Independent valuation report by CA Sanjay Jhajharia determined a floor price of ₹314.79.
Corrigendum issued to comply with SEBI ICDR Regulations 165 and 166A(1) following NSE observations.
The allotment will exceed 5% of the post-issue fully diluted share capital of the company.
Shareholders who have already voted can submit comments to the Company Secretary until April 26, 2026.
👀 What to Watch
Investors should review the valuation justification provided for this infrequently traded stock and monitor the impact of the 5% plus dilution on the capital structure. No immediate action is required unless shareholders wish to revise their feedback based on the new disclosures.
Chalet Hotels to Acquire Inder Residency Resort in Udaipur for ₹171 Crore
Chalet Hotels has approved the 100% acquisition of Seasons Hotels Private Limited, the owner of the 144-room Inder Residency Resort & Spa in Udaipur, for ₹171 crore. This marks the company's entry into the high-growth Rajasthan leisure market, aligning with its strategy to diversify into premium lifestyle destinations. The property, spread across 8.2 acres, will undergo significant refurbishment and repositioning, during which it will remain non-operative. While the target's FY25 turnover was ₹74.3 million, Chalet plans to create value through asset enhancement and potential room expansion.
Key Highlights
Acquisition of 100% equity in Seasons Hotels Private Limited for a cash consideration of ₹1,710 million
Target property is a 144-room resort on 8.2 acres in Udaipur, featuring extensive lawns and MICE facilities
The resort will be upgraded to an upper upscale destination and will be non-operative during the renovation phase
Target company reported a turnover of ₹74.3 million in FY24-25, compared to ₹103.5 million in FY23-24
The transaction is expected to be completed by May 15, 2026
👀 What to Watch
Investors should view this as a strategic long-term move into the lucrative Udaipur leisure market, though immediate revenue contribution will be limited due to the planned renovation shutdown. Monitor the timeline for the resort's reopening and its rebranding under Chalet's premium portfolio.
Chalet Hotels to Acquire Inder Residency Resort in Udaipur for ₹171 Crore
Chalet Hotels has approved the 100% acquisition of Seasons Hotels Private Limited, the owner of Inder Residency Resort & Spa in Udaipur, for a total consideration of ₹171 crore. This acquisition marks the company's entry into the high-growth Rajasthan leisure market and includes a 144-room resort spread across 8.2 acres. The property will be upgraded to a premium lifestyle destination and will remain non-operative during the refurbishment period. The transaction is expected to be completed by May 15, 2026, and will be funded via cash consideration.
Key Highlights
Acquisition of 100% equity in Seasons Hotels Private Limited for ₹1,710 million (₹171 crore)
Target asset is a 144-room resort on 8.2 acres in Udaipur, featuring expansive lawns and banqueting facilities
Target entity turnover was ₹74.3 million in FY25, down from ₹103.5 million in FY24
Property will be temporarily closed for upgrades to an upper upscale/premium lifestyle destination
Acquisition expected to close by May 15, 2026, with potential for future room expansion
👀 What to Watch
Investors should monitor the capital expenditure required for the planned upgrades and the timeline for the resort's reopening. While the acquisition strengthens Chalet's leisure portfolio, the asset will not contribute to immediate revenue during its renovation phase.
Vijay Kedia Resigns as Independent Director of Shalby Limited Effective April 30, 2026
Mr. Vijay Kishanlal Kedia has tendered his resignation as an Independent Director of Shalby Limited, effective from the close of business hours on April 30, 2026. He cited increasing professional commitments and time constraints as the primary reasons for stepping down after a three-year association with the board. The company and Mr. Kedia have confirmed there are no other material reasons for this departure. While Mr. Kedia is a high-profile investor, his exit from the board appears to be a routine transition rather than a reflection of internal issues.
Key Highlights
Resignation of Mr. Vijay Kishanlal Kedia (DIN: 00230480) effective April 30, 2026
Reason for departure cited as increasing professional commitments and time constraints
Mr. Kedia served on the Board of Directors for a period of approximately 3 years
Confirmation provided that no other material reasons exist for the resignation
Mr. Kedia continues to hold a Non-Executive Directorship at Atul Auto Ltd
👀 What to Watch
Investors should treat this as a routine board change as no governance concerns were raised. Monitor the company's future board appointments to ensure continued strong independent oversight.
Marshall Machines to Hold 7th CoC Meeting; Challenge Process for Bidders Scheduled
Marshall Machines Limited is currently undergoing a Corporate Insolvency Resolution Process (CIRP) under the IBC. The 7th meeting of the Committee of Creditors (CoC) is scheduled for April 16, 2026, to conduct a 'Challenge Process' between prospective resolution applicants. This process is a critical step in determining the future ownership of the company and the recovery for creditors. Shareholders should be aware that insolvency proceedings often result in significant equity dilution or complete write-offs.
Key Highlights
7th meeting of the Committee of Creditors (CoC) scheduled for April 16, 2026, at 3:00 PM.
Agenda includes running a 'Challenge Process' between Prospective Resolution Applicants to determine the best bid.
The meeting will also review the minutes of the 6th CoC meeting held on March 20, 2026.
The process is being managed by Mavent Restructuring Services LLP as the Resolution Professional.
Approval for a shorter notice period for the meeting is also on the voting agenda.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency; equity value is highly at risk of being wiped out depending on the resolution plan. Monitor the outcome of the challenge process for any signs of a successful turnaround or potential delisting.
Halder Venture to Raise Rs 25 Cr via 7.94 Lakh Warrants for Haldia Unit Expansion
Halder Venture Limited is raising approximately Rs 25 crore through the issuance of 7,93,650 convertible warrants at Rs 315 per warrant to P.K. Bio Link Private Limited. The proceeds are primarily earmarked for a new 500 MT edible oil refining unit in Haldia (Rs 11.50 crore) and augmenting working capital (Rs 11.30 crore). The company also aims to increase its rice mill capacity utilization from 50% to 80% to serve expanding foreign markets. This corrigendum provides necessary clarifications on pricing and fund utilization as requested by NSE and BSE.
Key Highlights
Issuance of 7,93,650 convertible warrants at Rs 315 per warrant to raise ~Rs 25 crore.
Allocation of Rs 11.50 crore for a new 500 MT edible oil refining unit at the Haldia facility.
Plan to increase rice mill capacity utilization from 50% to 70-80% to meet export demand.
P.K. Bio Link Private Limited to hold a 5.99% stake in the company post-conversion.
Funds to be utilized within 6 months of receipt for capital expansion and working capital.
👀 What to Watch
Investors should track the execution of the Haldia refining unit as it marks a significant capacity expansion into the edible oil sector. Monitor the warrant conversion process over the next 18 months for potential equity dilution.
Simbhaoli Sugars Cites CIRP and Staff Shortage for Delay in Financial Results
Simbhaoli Sugars Limited has responded to exchange clarifications regarding the non-submission of consolidated financial results. The company is currently undergoing a Corporate Insolvency Resolution Process (CIRP) effective July 11, 2024, which has led to the suspension of the Board's powers. Management cited several reasons for the delay, including a stay order from the NCLAT, the departure of key finance personnel, and a recent change in statutory auditors. The company is working to finalize results for the quarter ended September 30, 2025, but has not provided a specific timeline for completion.
Key Highlights
Company entered Corporate Insolvency Resolution Process (CIRP) on July 11, 2024.
NCLAT issued an interim order on July 24, 2024, staying further steps in the insolvency process.
Delay in results attributed to the departure of key finance staff and a change in statutory auditors.
Consolidated financial results for the quarter ended September 30, 2025, are still pending submission.
Operational focus on the cane crushing season further diverted managerial resources from financial reporting.
👀 What to Watch
Investors should remain extremely cautious as the company is in insolvency and failing to meet regulatory reporting deadlines. The lack of financial transparency and ongoing legal battles make this a high-risk situation.
Shalby Issues USD 13.27 Million SBLC for US Step-Down Subsidiary
Shalby Limited has issued a Standby Letter of Credit (SBLC) for an amount up to USD 13.27 million through IndusInd Bank. The beneficiary of this financial guarantee is Shalby Advanced Technologies, Inc. (SAT Inc.), which is the company's step-down subsidiary based in the USA. This move is intended to help the overseas unit secure credit facilities for its operational requirements. While the company expects no immediate material financial impact on its own operations, it represents a significant financial commitment to its international expansion.
Key Highlights
Issuance of Standby Letter of Credit (SBLC) totaling up to USD 13.27 million
Beneficiary is Shalby Advanced Technologies, Inc., a USA-based step-down subsidiary
Financial facility facilitated through IndusInd Bank Limited
Aims to assist the subsidiary in obtaining credit facilities for business needs
Transaction confirmed to be at arm's length with no promoter group interest
👀 What to Watch
Investors should monitor the operational progress of the US subsidiary, as the parent company has now increased its contingent liability to support the unit's creditworthiness. No immediate portfolio changes are necessary based on this routine financial support disclosure.
Marshall Machines CoC Approves Challenge Process Mechanism for Resolution Applicants
Marshall Machines Limited is currently undergoing a Corporate Insolvency Resolution Process (CIRP). In the 6th Committee of Creditors (CoC) meeting, which concluded voting on April 6, 2026, members approved a challenge process mechanism to evaluate and optimize bids from prospective resolution applicants. This step is intended to maximize the value of the company's assets. Additionally, the CoC ratified the costs incurred by the Resolution Professional as per CIRP regulations, indicating the process is advancing toward a potential resolution.
Key Highlights
6th CoC meeting held on March 20, 2026, with voting results finalized on April 6, 2026
Approval of a challenge process mechanism between Prospective Resolution Applicants to maximize recovery
Ratification of costs incurred by the Resolution Professional under Regulation 34 of CIRP
The company continues to be managed by the Resolution Professional during the insolvency period
👀 What to Watch
Investors should exercise extreme caution as equity value is typically significantly diluted or wiped out during insolvency resolutions. Monitor the outcome of the challenge process to see if a viable resolution plan is eventually approved by the NCLT.
HAL FY26 Revenue Hits Rs 32,250 Cr; Order Book Surges to Record Rs 2.54 Lakh Cr
Hindustan Aeronautics Limited (HAL) reported a provisional revenue of Rs 32,250 crores for FY 2025-26, a growth of 4.1% over the previous year despite global supply chain disruptions. The company's order book reached a massive Rs 2.54 lakh crores, driven by a landmark Rs 62,370 crore order for 97 LCA Mk1A aircraft. HAL is expanding its manufacturing capacity with new production lines at Nasik and diversifying into civil aviation and space launch services. The company also maintained strong shareholder returns with a total dividend payout of Rs 3,344 crores during the fiscal year.
Key Highlights
Annual revenue grew to Rs 32,250 crores in FY26 from Rs 30,981 crores in the previous fiscal.
Order book stands at a record Rs 2.54 lakh crores, providing revenue visibility for the next 7-8 years.
Secured major MoD contracts including 97 LCA Mk1A (Rs 62,370 cr) and 6 ALH CG (Rs 2,704 cr).
Operationalized a third LCA production line and a second HTT 40 line to accelerate deliveries.
Total dividend outflow reached Rs 3,344 crores, including an interim dividend of Rs 35 per share.
👀 What to Watch
HAL remains a robust long-term bet in the defense sector due to its massive order backlog and strategic capacity expansion. Investors should focus on the company's ability to navigate supply chain challenges to convert its record order book into timely revenue.
Halder Venture Credit Rating Upgraded to 'CRISIL BBB-/Stable' on Improved Financial Performance
CRISIL has upgraded Halder Venture Limited's long-term rating to 'CRISIL BBB-/Stable' from 'CRISIL BB+/Stable (Issuer Not Cooperating)' following improved data transparency and strong financial growth. The company reported a significant revenue jump to Rs 870.88 crore in FY25, with PAT nearly doubling to Rs 21.11 crore. While the group maintains a moderate financial risk profile with a gearing of 1.94x, it is currently executing a large Rs 155 crore capex for a new refinery and storage unit in Haldia. Liquidity is considered adequate with projected cash accruals of over Rs 22 crore against debt obligations of Rs 5 crore.
Key Highlights
Long-term credit rating upgraded to 'CRISIL BBB-/Stable' for Rs 387.27 crore bank facilities.
FY25 operating income grew to Rs 870.88 crore from Rs 646.19 crore in FY24.
Net profit (PAT) increased to Rs 21.11 crore in FY25 compared to Rs 11.67 crore in FY24.
Ongoing Rs 155 crore capex in Haldia for storage and refinery units, funded by Rs 75 crore debt.
Interest coverage ratio improved to 2.55 times in FY25 from 2.11 times in FY24.
👀 What to Watch
The rating upgrade and removal from the 'non-cooperating' category signal improved corporate governance and creditworthiness. Investors should monitor the timely commissioning of the Haldia refinery in 2027, as it is a key driver for future margin expansion.
Halder Venture to Raise ₹25 Crore via Preferential Issue of 7.93 Lakh Warrants at ₹315
Halder Venture Limited is seeking shareholder approval to raise approximately ₹25 crore through the issuance of 7,93,650 convertible warrants to P.K. Bio Link Pvt. Ltd., a non-promoter entity. The warrants are priced at ₹315 each, which includes a premium of ₹305 per share. To facilitate this, the company is also proposing to increase its authorized share capital from ₹13.425 crore to ₹18.425 crore. This capital infusion is intended to support the company's growth and operational needs.
Key Highlights
Proposed issuance of 7,93,650 convertible warrants to non-promoter P.K. Bio Link Pvt. Ltd.
Total fundraise amount fixed at ₹24,99,99,750 at an issue price of ₹315 per warrant.
Authorized share capital to be increased by ₹5 crore to a total of ₹18.425 crore.
Warrant holders must pay 25% of the total consideration upfront, with the remaining 75% due within 18 months upon conversion.
Independent valuation report determined a minimum price of ₹314.79 per equity share, supporting the ₹315 issue price.
👀 What to Watch
The fundraise at a premium suggests confidence from external investors; however, existing shareholders should monitor the potential equity dilution of over 5% upon warrant conversion.
Haleos Labs Seeks Approval for ₹20 Crore Corporate Guarantee for Subsidiary Mahi Drugs
Haleos Labs Limited has issued a postal ballot notice to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee of up to USD 2.2 million (approximately ₹20 crores) in favor of RBL Bank. This guarantee is required to secure an External Commercial Borrowing (ECB) facility for its subsidiary, Mahi Drugs Private Limited. Shareholders can cast their votes via remote e-voting between March 31 and April 29, 2026.
Key Highlights
Proposed corporate guarantee of USD 2.2 million (approx. ₹20 crores) for subsidiary Mahi Drugs Private Limited
Guarantee to secure External Commercial Borrowing (ECB) facility from RBL Bank
Shareholder approval sought via postal ballot through remote e-voting process
E-voting period scheduled from March 31, 2026, to April 29, 2026
Final results of the postal ballot to be declared on May 1, 2026
👀 What to Watch
Investors should monitor the parent company's contingent liabilities and the performance of Mahi Drugs to ensure the debt is well-serviced. This move indicates financial support for subsidiary expansion but increases the parent's risk profile.
Halder Venture to Raise ₹25 Crore via Preferential Issue of Convertible Warrants
Halder Venture Limited's board has approved a significant fundraise of approximately ₹25 crore through the issuance of 7,93,650 convertible warrants. These warrants are priced at ₹315 each (including a ₹305 premium) and will be allotted to P.K. Bio Link Private Limited, a non-promoter entity. To accommodate this issuance, the company is increasing its authorized share capital from ₹13.425 crore to ₹18.425 crore. Additionally, the company has transitioned its internal audit function to M/s J Kumar Jain & Associates following the resignation of the previous auditor.
Key Highlights
Approved issuance of 7,93,650 convertible warrants at ₹315 per warrant to raise ₹24.99 crore.
Authorized share capital increased from ₹13.425 crore to ₹18.425 crore to facilitate the issue.
Preferential allotment targeted at a single non-promoter investor, P.K. Bio Link Private Limited.
Appointment of M/s J Kumar Jain & Associates as Internal Auditor for the financial year 2025-2026.
The fundraise and capital increase are subject to shareholder approval via postal ballot.
👀 What to Watch
Investors should view the ₹25 crore capital infusion as a positive indicator for growth and monitor the company's upcoming postal ballot for shareholder approval. The warrant pricing at ₹315 serves as a key valuation benchmark for the stock.
Halder Venture to Raise ₹25 Crore via Preferential Issue of 7.93 Lakh Warrants
Halder Venture Limited has approved the issuance of 7,93,650 convertible warrants to P.K. Bio Link Private Limited, a non-promoter entity, at a price of ₹315 per warrant. This preferential allotment aims to raise approximately ₹25 crore, subject to shareholder approval via postal ballot. To facilitate this, the company is increasing its authorized share capital from ₹13.425 crore to ₹18.425 crore. Additionally, the board has appointed M/s J Kumar Jain & Associates as the new internal auditor following the resignation of the previous firm.
Key Highlights
Approved issuance of 7,93,650 convertible warrants at ₹315 per warrant (including ₹305 premium).
Total fundraise amount is approximately ₹24,99,99,750 from a non-promoter entity.
Authorised share capital increased from ₹13.425 crore to ₹18.425 crore.
Appointment of M/s J Kumar Jain & Associates as Internal Auditor for FY 2025-26.
Warrants are convertible into one fully paid-up equity share of ₹10 face value each.
👀 What to Watch
Investors should monitor the specific purpose of the ₹25 crore fundraise and the potential equity dilution upon warrant conversion. The pricing of ₹315 per warrant serves as a key valuation benchmark for the company.
Halder Venture to Raise ₹25 Crore via Preferential Issue of 7.94 Lakh Convertible Warrants
Halder Venture Limited has approved a significant fundraise of approximately ₹25 crore through the preferential allotment of 7,93,650 convertible warrants to P.K. Bio Link Private Limited, a non-promoter entity. The warrants are priced at ₹315 each, representing a substantial premium over the ₹10 face value. To accommodate this and future requirements, the company is increasing its authorized share capital from ₹13.425 crore to ₹18.425 crore. The board also transitioned its internal audit function to M/s J Kumar Jain & Associates following the resignation of the previous auditor.
Key Highlights
Approved issuance of 7,93,650 convertible warrants at a price of ₹315 per warrant (including ₹305 premium).
Total capital to be raised through the preferential issue is approximately ₹24.99 crore.
Authorised share capital increased from ₹13.425 crore to ₹18.425 crore to facilitate the issuance.
P.K. Bio Link Private Limited identified as the sole non-promoter investor for this round.
Appointment of M/s J Kumar Jain & Associates as Internal Auditor for the financial year 2025-2026.
👀 What to Watch
Investors should track the shareholder approval via postal ballot and the subsequent utilization of the ₹25 crore proceeds for growth initiatives. While the fundraise is positive, be mindful of the eventual equity dilution when warrants are converted.
